H. Lee Moffitt Cancer Center and Research Institute
Trial Pipeline
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
NCT07476001
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
NCT07194044
Digoxin Medulloblastoma Study
NCT06701812
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
NCT06961357
Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL
NCT07250087
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
NCT07276386
Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs
NCT07222995
A First-in-Human Study of FID-022 in Solid Tumor Patients
NCT07249775
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
NCT07047885
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
NCT07030400
The MIND-BC Study: MIND Diet for Breast Cancer Cognition
NCT07018986
Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma
NCT07007273
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
NCT06745882
Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
NCT06047977
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
NCT06947083
ProSalud in Latinos Living in Rural/Agricultural Communities Within Moffitt's Catchment Area
NCT07218848
Creation of an Infrastructure to Support Delivery of mHealth Interventions for Cancer Patients
NCT06909357
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
NCT06553885
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
NCT06760156
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
NCT06855212
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer
NCT06833502
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
NCT06660355
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
NCT06238921
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
NCT06660368
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
NCT06511882
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
NCT06121180
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
NCT06691035
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
NCT06193486
Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening
NCT06745895
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
NCT06597565
Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)
NCT06560398
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
NCT06553872
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
NCT06409390
Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer
NCT06497569
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
NCT06435351
App for Reducing Cravings to Smoke
NCT06088498
Exercise Prehabilitation for Locoregional Esophageal Cancer
NCT06430346
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
NCT06295159
Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)
NCT06423950
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
NCT06350318
High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)
NCT06337552
Avapritinib With Decitabine in Patients With SM-AHN
NCT06327685
Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer
NCT06423963
Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
NCT06305676
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
NCT06109467
Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06144606
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
NCT06104592
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
NCT05809752
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
NCT06001268
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
NCT05757219
CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
NCT05581030
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
NCT05651828
Outreach Core Activities
NCT05832177
Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations
NCT05687188
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
NCT05732961
Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology
NCT05664178
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
NCT05558124
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
NCT05751941
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
NCT05528133
Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer
NCT05665504
Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
NCT05526989
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
NCT05524935
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
NCT05504707
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
NCT05378464
Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma
NCT05301283
Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
NCT05316129
Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
NCT05024552
Study of Screening Brain MRIs in Stage IV Breast Cancer
NCT05115474
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
NCT04923542
Using Aspirin to Improve Immunological Features of Ovarian Tumors
NCT05080946
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
NCT05325632
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
NCT05070403
Axitinib + Ipilimumab in Advanced Melanoma
NCT04996823
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
NCT04741997
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
NCT04588545
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
NCT04562129
Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board
NCT04343365
Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
NCT04275557
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
NCT03495427
NutritiOUs fRuIts and veggieS to Improve Health: A Culinary Medicine Intervention
NCT06926972
Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center
NCT06712797
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
NCT06734130
Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)
NCT06519097
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
NCT06236425
Study of CG0070 After Transurethral Resection in Patients With IR NMIBC
NCT06253845
Investigation of MP Pollution in the Human Respiratory System and Its Relationship to Lung Cancer
NCT06530615
Breast Cancer Survivors RESET (Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools): A Pilot, Feasibility Study
NCT07101861
Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC
NCT06137274
REFLECT: Reproductive Education and Fertility Links for Cancer Treatment
NCT06199726
The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response
NCT06050395
Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC
NCT05768347
Senior Adult Hepatobiliary Prehab Study
NCT05921552
The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors
NCT05798780
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
NCT05681780
Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy
NCT05763563
Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients
NCT05675059
Enhancing Long-Term Smoking Abstinence Among Cervical Cancer Survivors (Project ACCESS)
NCT05645146
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
NCT05628883
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
NCT05692596
Early Supportive Care and Nutritional Support in Adults With Pancreatic Cancer
NCT05438927
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 185 |
| Phase 2 | 285 |
| Phase 3 | 1 |
Therapeutic Areas
What the Pipeline for H. Lee Moffitt Cancer Center and Research Institute Shows
According to the ClinicalTrials.gov registry, H. Lee Moffitt Cancer Center and Research Institute is linked to 562 US clinical trials across every stage of research activity. Of those, 431 studies are currently recruiting — about 77% of the sponsor's indexed portfolio — and 62 are already marked complete, representing roughly 11% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for H. Lee Moffitt Cancer Center and Research Institute reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 470 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for H. Lee Moffitt Cancer Center and Research Institute is Prostate Cancer with 12 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.